In addition to Pfizer’s (PFE) product developments, it has a few recent pipeline and corporate developments. Let’s take a look at them.
Pfizer has reported the following recent corporate developments:
- In January 2017, ICU Medical modified its merger agreement with Pfizer, announced in October 2016, to acquire Hospira’s global infusion systems business. ICU Medical reduced the purchase price to $900.0 million from $1.0 billion due to the performance of Hospira’s global infusion systems business.
- Pfizer completed the acquisition of the small molecule anti-infective business from AstraZeneca (AZN) in December 2016, which will strengthen its anti-infective business.
Pfizer has reported the following recent pipeline developments:
- The FDA (U.S. Food and Drug Administration) has accepted for priority review Pfizer’s and EMD Serono’s BLA (Biologics License Application) for avelumab for the treatment of Merkel cell carcinoma. EMD Serono is the biopharmaceutical business of Merck KGaA in the United States and Canada.
- Pfizer announced that its pivotal REFLECTIONS B3271002 study, which evaluated the safety and efficacy of the biosimilar PF-05280014 for the treatment of HER2+ (human epidermal growth factor receptor 2 positive) metastatic breast cancer, met its primary endpoint in November 2016. The drug was compared to Genentech’s Herceptin.
- Pfizer announced that its REFLECTIONS B532-02 study evaluating the biosimilar PF-06410293 in combination with methotrexate for the treatment of rheumatoid arthritis met its primary endpoint in January 2017. The drug was compared to AbbVie’s (ABBV) Humira.
To divest the risk, you can consider investing in ETFs such as the Fidelity MSCI Health Care ETF (FHLC), which holds ~6.7% of its total investments in Pfizer, 2.9% in Biogen (BIIB), and 4.6% in Gilead Sciences (GILD).